Zacks Investment Research upgraded shares of PureTech Health (NASDAQ:PRTC) from a hold rating to a buy rating in a report issued on Wednesday morning, Zacks.com reports. They currently have $45.00 price objective on the stock.
According to Zacks, “PureTech Health plc is a clinical-stage biotherapeutics company. It engages in discovering, developing and commercializing medicines for devastating diseases, including inflammatory and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders. PureTech Health plc is based in Boston, Massachusetts. “
Separately, SVB Leerink lowered their price target on PureTech Health from $76.00 to $70.00 and set an outperform rating for the company in a report on Friday, January 7th.
About PureTech Health
PureTech Health plc, a clinical stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and dementia-related psychosis; a hydrogel platform technology to treat obesity and other chronic metabolic diseases; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; a immunomodulation platform to treat chronic and acute inflammatory disorders; therapies for immune-mediated diseases based on a rationally-defined consortia of human microbiome-derived bacteria; and a digital treatments to treat cognitive dysfunction associated with neurology and psychiatry conditions.
Read More: Economic Bubble
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for PureTech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health and related companies with MarketBeat.com's FREE daily email newsletter.